A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.
Zhou Q, Wu L, Hu P, An T, Zhou J, Zhang L, Liu XQ, Luo F, Zheng X, Cheng Y, Yang N, Li J, Feng J, Han B, Song Y, Wang K, Zhang L, Fang J, Zhao H, Shu Y, Lin XY, Chen Z, Gan B, Xu WH, Tang W, Zhang X, Yang JJ, Xu X, Wu YL.
Zhou Q, et al. Among authors: xu wh, xu x.
Clin Cancer Res. 2022 Mar 15;28(6):1127-1135. doi: 10.1158/1078-0432.CCR-21-2595.
Clin Cancer Res. 2022.
PMID: 34740925
Free PMC article.
Clinical Trial.